secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-310572
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports positive Phase 1b results for oral STAT6 degrader KT-621 in atopic dermatitis
--------------------------------------------------------------------------------

- KT-621 achieved 98% median STAT6 degradation in blood and 94% in skin lesions at Day 29 across both dose groups.
- Mean EASI reduction of 63% and mean peak pruritus NRS reduction of 40% across all patients; rapid onset by Day 8.
- Type 2 biomarker reductions: TARC down 74% in patients with baseline ≥1,600 pg/mL; Eotaxin-3 reductions numerically exceeded dupilumab at 52 weeks.
- First known demonstration of IL-31 reduction and FeNO reduction in AD patients via IL-4/13 pathway blockade.
- Well-tolerated with no SAEs, no treatment-related AEs, no conjunctivitis; Phase 2b BROADEN2 ongoing (data mid-2027) and BREADTH asthma trial starts 1Q26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525310572/0001193125-25-310572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312525310572/d69739d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-310572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer